M ethotrexate (MTX) is widely used in the treatment of severe forms of psoriasis and psoriatic arthritis. A number of studies have documented its efficacy and the high degree of patient compliance (1) (2) (3) (4) (5) .
The many complications that are associated with MTX have been significantly reduced by using low and intermittent doses. However, the potential for hepatic fibrosis and cirrhosis remains a major concern with long term treatment. The data from the literature reveal an incidence of hepatic cirrhosis varying from 0% (6,7) to 25.6% (8) .
Guidelines formulated by Roenigk and co-workers (9) in 1972, and later revisions in 1973 (10) , 1982 (11) and 1988 (12) offer recommendations on the indications for and the dosage of MTX, and on initial and follow-up assessments of psoriatic patients. In addition to the clinical and laboratory assessments of renal, hematopoietic and hepatic functions, the guidelines recommend histological evaluation of a pre-MTX liver biopsy and repeat annual biopsies while the patient is on the drug or after every 1 to 1.5 g cumulative MTX intake.
While the duration of treatment and the cumulative dose seem to have an important role in the evolution of MTXinduced hepatotoxicity, a number of other risk factors have been identified. These include alcohol, obesity, diabetes mellitus, increased age and pre-existing liver disease (6, 8, 13, 14) .
Several studies have attempted to clarify the relation between MTX-induced hepatic fibrosis and cirrhosis, and other risk factors such as age, diabetes, obesity, alcohol ingestion, duration of treatment or cumulative dose (14) (15) (16) , with some conflicting results. We report our experience with 104 psoriatic patients who received MTX weekly and underwent annual liver biopsies for histological monitoring.
METHODOLOGY Histology:
All liver biopsies between 1979 and 1990 from psoriatic patients on MTX therapy were retrieved from the files of the Division of Anatomical Pathology at the Victoria General Hospital, Halifax, Nova Scotia. The biopsies had been serially cut to be 5 µm thick and all had a minimum of three hematoxylin and eosin stained sections, one Masson's trichrome stained section for connective tissue and one section stained for iron using Perls' reaction. When appropriate, one or more of the following additional stains were done: periodic acid Schiff with or without pretreatment with diastase, Shikata orcein stain for hepatitis B virus surface antigen and van Gieson stain for connective tissue. The slides were reviewed unblinded by an author and the following histological variables were tabulated: degree of steatosis; amount and cellular distribution of stainable iron; presence of centrilobular sinusoidal fibrosis; amount of portal inflammation; extent of portal fibrosis; presence of periportal inflammation; presence of periportal fibrosis; presence of bridging fibrosis; degree of hepatocellular nuclear variability; presence and extent of hepatocellular degeneration; presence and extent of hepatocellular necrosis; presence and extent of lobular inflammation; and presence of cirrhosis.
Steatosis was graded 0 when absent, +1 (mild) when centrilobular, +2 (moderate) when centrilobular and midzonal, and +3 (severe) when panlobular in distribution. The stainable iron, the inflammation in portal, periportal and lobular areas, and both hepatocellular degeneration and necrosis were graded as absent (0), or empirically as mild (+1), moderate (+2) or severe (+3).
Periportal fibrosis, bridging fibrosis and cirrhosis were graded as absent (0) or present (1) . Cirrhosis was diagnosed only in the presence of regenerative nodules surrounded by fibrous tissue. La consommation occasionnelle d'alcool n'est associée à aucun accroissement de risque. Trois patients chez qui la cirrhose s'est installée sur une période de deux ans de traitement au MTX aux doses normales pourraient représenter une sous-catégorie de patients atteints de psoriasis présentant une fragilité hépatique accrue associée au MTX. Trois autres patients dont la fibrose hépatique grave avait régressé à l'arrêt du traitement par MTX et qui ont développé une récurrence accélérée de fibrose hépatique grave à la reprise du traitement par MTX permettent de supposer la possibilité d'une sensibilité spéciale au médicament. Ces six patients rappellent la nécessité de surveiller attentivement au moyen de biopsies hépatiques régulières les patients atteints de psoriasis traités au MTX.
The biopsies were designated grades according to the system proposed by Roenigk et al (11) 
Patient data:
The inclusion criteria for this study were patients with psoriasis who had a pre-MTX liver biopsy and who had regular annual follow-up biopsies while on MTX. All patients included in the study were screened for risk factors before MTX was instituted and were followed up clinically, with routine blood and biochemical screening while on MTX. Excluded were patients with psoriasis receiving MTX for less than one year and those on MTX for whom baseline or regular annual follow-up biopsies were not available for histological evaluation.
Clinical data were extracted from medical records and compared with the histological grades. The following clinical data were documented: sex, age at start of therapy, indications, dosage and mode of administration of MTX, cumulative dose of MTX before each follow-up biopsy, body height and weight, clinical diagnosis of obesity, presence of diabetes mellitus and alcohol ingestion.
MTX was given in 5 to 25 mg weekly doses either as a single dose or as one-third of the dose every 12 h once per week. The estimated annual dose ranged from 1 to 1.5 g/ patient.
According to the guidelines, MTX was discontinued in all patients with histological grades IIIB or IV. Patients with grade IIIA liver biopsies continued to receive MTX but were monitored with regular liver biopsies either annually, when the periportal fibrosis was mild, or at six-to nine-month intervals, when there was evidence of impending grade IIIB change. Statistics: Differences in years of follow-up between sex groups and between the alcohol, obesity and diabetes risk factor groups were assessed by the Wilcoxon rank sum test. Differences in follow-up between initial biopsy grade, final biopsy grade and age were assessed by Spearman's correlation coefficient. Differences in initial biopsy grade between males and females, and among the diabetes, obesity and alcohol risk factor groups were assessed by the Wilcoxon rank sum test. Differences in initial biopsy grade by age were assessed by Spearman's correlation coefficient. Odds ratios for the risk of liver biopsy grade progression, and for the risk of progression to grades IIIB and IV, for obesity, diabetes and alcohol risk factors were estimated by logistic regression (17) . Age and years of follow-up were initially used as covariates and found to be nonsignificant. Therefore, they were omitted from the model producing the final estimates.
All analyses were done using SAS statistical software (SAS Institute, North Carolina).
RESULTS
A total of 104 patients fulfilled the inclusion criteria (Table 1 ). There were 45 females, mean age 44.2 years (range 16 to 71), and 59 males, mean age 39.2 years (range 18 to 70).
Mean follow-up was 3.5 years for female patients, 4.1 years for males and averaged 3.8 years for all patients (range one to 11) ( Table 2 ). There were no statistical differences in followup by sex (P=0.67), age (comparing younger than 40 years with older than 40 years) (P=0.28), alcohol consumption status (P=0.92), obesity status (P=0.80), diabetes status (P=0.95), or initial liver biopsy grade (P=0.08).
Thirty-five patients, 20 females and 15 males, were identified as obese. Obesity was at least 20% above normal body mass index in 28 patients (72%). Obesity was determined from body weight combined with clinical statement of 'obese' in seven patients (18%) and from clinical statement alone in four (10%). Ten patients, nine females and one male, had biochemically determined diabetes mellitus (Table 3).
All patients had been advised against drinking alcoholic beverages before MTX administration. Thirty-seven patients, 13 females and 24 males, admitted to social or occasional alcohol consumption, which was defined as no greater than three drinks per week (a drink constituted 30 mL of hard liquor, 118 mL of wine or 355 mL of beer) (personal communication).
There were 477 biopsies, 104 baseline biopsies (pre-MTX treatment) and 373 annual follow-up biopsies. The histological grading of the liver biopsies is shown in Figure 4 . Eighty patients started with baseline grade I liver biopsies, 16 with grade II liver biopsies and eight (five females and three males) with grade IIIA biopsies. None of the biopsies showed evidence of alcoholic hepatitis, chronic viral hepatitis or 
Figure 4) Progression of liver biopsy initial grades. Numbers inside brackets refer to the number of patients
increased accumulation of stainable iron. There were no statistically significant differences in the initial biopsy grade by sex (P=0.67) or alcohol use status (P=0.82). However, the obese group (P=0.006) and the diabetes group (P=0.004) had a higher percentage of grades II and IIIA biopsies, and initial biopsy grade was positively correlated with age (P=0.003). Figure 4 also shows the progression of the initial grades at the end of the study. Of the 80 patients with grade I baseline biopsies, 37 continued with the same grade, 10 patients developed grade II changes, 17 developed grade IIIA changes, 14 developed grade IIIB changes and two developed cirrhosis. Eight of the 16 patients with grade II baseline biopsies developed grade IIIA changes and three developed grade IIIB changes. Four patients in the grade IIIA baseline group developed grade IIIB changes and one developed cirrhosis. The retrograde change from a higher to a lower grade seen in three patients with baseline grade II and one patient with initial grade IIIA is attributed to biopsy sampling variation. Increased biopsy grade progression was associated with obesity (P=0.001), but not with alcohol (P=0.93) and diabetes (P=0.42) ( Table 4) .
At the end of the study 40 patients had grade I liver biopsies, 13 had grade II liver biopsies, 27 had grade IIIA liver biopsies, 21 had grade IIIB liver biopsies and three (two females and one male) had final grade IV liver biopsies. Progression to final grades IIIB and IV was associated with diabetes (P=0.02) but not with obesity or alcohol use ( Table 4) .
The three patients who developed cirrhosis did so within two years of MTX therapy (Table 5 ). These were one male and two females, age 22, 42 and 66 years, respectively. The pre-MTX biopsies were grade I in two patients and grade IIIA in one. All three were obese and only one admitted to occasional alcohol consumption.
The three patients who had MTX stopped because of grade IIIB liver biopsy after three to six years (average 4.3) of treatment are described in Table 6 . After two to three years of withdrawal from MTX, the liver histology improved to grades I, II and IIIA. However, the liver grades reverted back to IIIB after one to two years (average 1.3) of MTX resumption.
DISCUSSION
Hepatic fibrosis and cirrhosis are the most serious side effects of MTX therapy for psoriasis. Routine monitoring of liver function tests does not reflect the slow progressive underlying fibrosis with minimal inflammation due to MTX. On the other hand, several studies have shown that histological examination of liver biopsies is the most accurate available means of monitoring MTX-induced hepatotoxicity and minimizing the risk of cirrhosis (4, (18) (19) (20) (21) (22) . Nevertheless controversy exists on the justification for liver biopsies before treatment with MTX. This issue is especially debated when applied to patients with rheumatoid arthritis because it has been shown that such patients are at a lower risk of developing serious MTX-related hepatotoxicity (14, 23, 24) . As a result of this controversy, the latest guidelines (12) recommend that the baseline (pre-MTX therapy) biopsy be postponed in some patients for up to four months after MTX treatment initiation to assess the initial response to the drug. If long term MTX treatment is anticipated, liver biopsy is then to be taken (12) . The delay in obtaining a baseline liver biopsy may be justified, particularly in patients with no clinical or biochemical suggestion of preexisting risks of liver disease. This risk includes obesity, diabetes and history of heavy alcohol consumption. All patients in this study had pre-MTX biopsies because of a consensus among the dermatologists and gastroenterologists in our institution to adhere to the recommendations proposed in the 1973 guidelines from the International Cooperative Group (10) . Moreover, a number of investigators have demonstrated significant fibrosis and even cirrhosis in psoriatic patients before MTX therapy (6, 8, 25) . In this series, eight patients (7.7%) had pre-MTX liver biopsies with IIIA changes. Because both diabetes and obesity predispose to liver fibrosis and occasionally to cirrhosis (26) , assessment of a pre-MTX liver biopsy should be helpful to identify patients at a particularly increased risk for an accelerated MTX hepatotoxicity.
The small number of patients (eight) with pre-MTX grade IIIA liver biopsies in this study did not allow definitive statistical conclusions for prediction of the outcome with prolonged MTX treatment. The progression of five patients (62.5%) in this group to bridging fibrosis and cirrhosis may suggest an increased risk with presence of a preexisting liver pathology. Other studies have shown a similar conclusion (16) . On the other hand, three of the five patients who developed advanced liver fibrosis in this study were obese, one was obese and diabetic, and one had no known risk factor. We believe that pre-MTX liver biopsies, even in the absence of known risk factors, provide valuable baseline histological information that allows not only detection of subclinical liver pathology, but also assessment of the rate at which MTX-induced hepatotoxicity may evolve in a particular patient.
Our results reiterate the previously reported increased risk for MTX-induced hepatotoxicity in obese and diabetic patients. However, the risk of severe hepatic fibrosis and cirrhosis in our series is found only in diabetic patients. There is reported evidence that alcohol accentuates the hepatotoxic- ity potential of MTX (6, 7, 27 ), but we did not find a statistically significant correlation with alcohol consumption in our patient population. All our patients had been warned at the outset of the adverse effect of alcohol while on MTX; the lack of statistical correlation may indicate this group of patients were generally compliant. However, 35 patients did admit to social drinking. As expected, the determining risk factor is the quantity of alcohol consumed (14) . Other investigators have found that history of pretreatment alcohol consumption does not increase risk of MTX-induced hepatotoxicity (15) . We believe that patients should continue to be instructed to abstain from drinking while on MTX.
Our findings of 19% of grade IIIB and 3% of grade IV in our patients agree with those reported by the International Cooperative Group (6) and are much lower than those in the Scandinavian studies (8, 13) . The higher Scandinavian results are thought to be due to longer years of exposure to MTX, higher cumulative doses of MTX or both.
The three patients in this series who developed cirrhosis over two years of standard MTX therapy may represent a subgroup of patients with an unusual high hepatic susceptibility to MTX. These patients underline the importance of regular follow-up liver biopsies while patients are on MTX. Zachariae and Sogaard (18) have suggested that MTXinduced cirrhosis is 'benign' compared with alcoholic cirrhosis and that MTX can cautiously be continued despite biopsy-proven cirrhosis. In contrast, Gilbert et al (19) reported three patients who required liver transplantation for MTX-induced cirrhosis. In our practice, we have followed the recommended guidelines and discontinued MTX in all patients with grades IIIB or IV and instead used alternative treatment.
Of interest are the three patients who were given MTX after it had been discontinued for two to three years because of grade IIIB liver biopsies (Table 6 ). These patients received alternative therapy until their interim biopsies showed improved histology not contraindicating the use of MTX. All three patients developed an accelerated progression to grade IIIB once MTX was reinstituted. This previously unreported feature raises the possibility of an acquired increased susceptibility to MTX. Newman and colleagues (15) have documented improvement in the histological status of the liver upon cessation of MTX but have not reported an accelerated hepatotoxicity upon resumption of MTX. In their experience, some patients did not develop fibrosis or cirrhosis upon resumption of MTX. They do recommend, however, followup liver biopsy at shorter intervals in these patients.
This study was completed before laboratory diagnosis of hepatitis C virus (HCV) became available, and because a number of nonspecific histological features of chronic HCV infection and MTX hepatotoxicity (such as portal infiltrate, steatosis and fibrosis) overlap, it may be argued that some of the pre-MTX grade IIIA liver biopsies are related to HCV. The absence of more characteristic histological features, ie, hepatocellular necrosis, sinusoidal lymphocytosis and portal lymphoid follicles, makes the possibility of chronic HCV infection less likely, however.
CONCLUSIONS
We report the first Canadian study on MTX-induced liver injury in patients with psoriasis. Despite close follow-up protocol and adherence to strict guidelines, this study reiterates the strong hepatotoxic potential of MTX in patients with psoriasis, and the increased risk in patients who are obese and diabetic. An unusual finding in our study is the unpredictable rapid histological deterioration of three patients' liver biopsies linked with obesity, pre-existing mild hepatic fibrosis and re-exposure to MTX after MTX was discontinued because of high grade fibrosis. 
